22 October 2025 – 1 mins read
PARIS, FRANCE, 22 October 2025 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year to date and the third quarter of 2025.
Ipsen’s financial results for the first nine months of 2025 were published on 22 October 2025.
An investor and analyst conference call took place on the same day.
Webcast RecordingWe are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience.
Our pipeline is fueled by internal and external innovation and supported by nearly 100 years of development experience and global hubs in the U.S., France and the U.K. Our teams in more than 40 countries, and our partnerships around the world, enable us to bring medicines to patients in more than 100 countries.
Discover Ipsen, our medicines and key figures, our objectives and our strategy.
If you are experiencing difficulties registering for the investor and analyst conference call, please contact: khalid.deojee@ipsen.com
Click on a star to rate it!
Vice President, Investor Relations
Senior Manager, Investor Relations
Ipsen Delivers Strong Growth and Expands Oncology Pipeline
H1 Results: a strong first half of 2025
H1 2025 Results
Q1 2025 sales update
2024: A year of achievements and progress
Strong growth and expanding pipeline in the first half of 2024 drive raised guidance
Ipsen delivers FY 2023 results and anticipates four launches in 2024
2023 year to date and third-quarter sales results
A strong first half of 2023
Ipsen FY/Q4 2022 results–A word from CEO David Loew
